Shan Lian, Wenyong Yang, Yan Zeng, Ranran Tang, Kui Wang. Targeted nano-drug delivery systems for tumor immunotherapy[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101408
Citation:
Shan Lian, Wenyong Yang, Yan Zeng, Ranran Tang, Kui Wang. Targeted nano-drug delivery systems for tumor immunotherapy[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101408
Shan Lian, Wenyong Yang, Yan Zeng, Ranran Tang, Kui Wang. Targeted nano-drug delivery systems for tumor immunotherapy[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101408
Citation:
Shan Lian, Wenyong Yang, Yan Zeng, Ranran Tang, Kui Wang. Targeted nano-drug delivery systems for tumor immunotherapy[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101408
a. West China School of Basic Medical Sciences & Forensic Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;
b. Department of Neurosurgery, Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, The Third People’s Hospital of Chengdu, Chengdu, 610041, P. R. China;
c. Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, 453199, P. R. China;
d. Nanjing Women and Children’s Healthcare Institute, Women’s Hospital of Nanjing Medical University (Nanjing Women and Children’s Healthcare Hospital), Nanjing, 210004, P. R. China
While being a safe and effective precision therapy strategy, tumor immunotherapy still fails in many patients due to immunosuppressive microenvironment. Emerging evidence has indicated that the targeted nano-drug delivery systems can accurately deliver therapeutic agents to potentiate the efficacy of immunotherapy. This review will outline recent advances in applying targeted nano-drug delivery systems in immunotherapy, with an emphasis on their crucial roles in regulating innate immunity response, adaptive immunity response, and immunogenic cell death. We will also discuss the current challenges and future opportunities for the clinical translation of targeted nano-drug delivery systems for tumor immunotherapy.